NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis $1.59 +0.05 (+3.25%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Nephros Stock (NASDAQ:NEPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nephros alerts:Sign Up Key Stats Today's Range$1.59▼$1.5950-Day Range$1.36▼$1.8752-Week Range$1.36▼$4.04Volume439 shsAverage Volume8,091 shsMarket Capitalization$16.76 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewNephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More… My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Nephros Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreNEPH MarketRank™: Nephros scored higher than 44% of companies evaluated by MarketBeat, and ranked 740th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNephros has only been the subject of 1 research reports in the past 90 days.Read more about Nephros' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nephros is -17.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nephros is -17.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNephros has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nephros' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.12% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently increased by 1,750.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNephros does not currently pay a dividend.Dividend GrowthNephros does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.12% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently increased by 1,750.00%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentNephros has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nephros insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Nephros is held by insiders.Percentage Held by Institutions41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nephros' insider trading history. Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address NEPH Stock News HeadlinesNephros Announces Third Quarter 2024 Financial ResultsSouth Orange, NJ - November 7, 2024 - Nephros, Inc. (NASDAQ: NEPH), a prominent water technology company specializing in filtration solutions for medical and commercial markets, revealed its finanNovember 17, 2024 | americanbankingnews.comNephros, Inc. (NASDAQ:NEPH) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...November 21, 2024 | Wyatt Investment Research (Ad)Results: Nephros, Inc. Confounded Analyst Expectations With A Surprise ProfitNovember 11, 2024 | finance.yahoo.comNephros, Inc. (NEPH) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comNephros’s Strategic Growth and Profitability Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comNephros Inc (NEPH) Q3 2024 Earnings Call Highlights: First Profitable Quarter and Strategic ...November 9, 2024 | finance.yahoo.comNephros, Inc. Reports First Profitable Quarter in 2024November 9, 2024 | markets.businessinsider.comSee More Headlines NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed this year? Nephros' stock was trading at $3.46 at the start of the year. Since then, NEPH shares have decreased by 54.0% and is now trading at $1.59. View the best growth stocks for 2024 here. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) posted its earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.02. The company earned $3.25 million during the quarter. Nephros had a negative net margin of 6.86% and a negative trailing twelve-month return on equity of 11.39%. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nephros own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/08/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+214.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-6.86% Pretax Margin-6.86% Return on Equity-11.39% Return on Assets-8.30% Debt Debt-to-Equity RatioN/A Current Ratio6.95 Quick Ratio4.02 Sales & Book Value Annual Sales$14.24 million Price / Sales1.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book2.04Miscellaneous Outstanding Shares10,540,000Free Float10,112,000Market Cap$16.76 million OptionableNot Optionable Beta1.19 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:NEPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.